EU Accession Reference Pricing
Add bookmarkInternational reference pricing has grown from an evolving cost-containment philosophy in Western Europe, to a trusted policy tool readily adopted by emerging markets around the world. As, Croatia, Macedonia and Turkey are considered more seriously for EU accession, pharmaceutical budgetary controls will be one aspect that enables them to conform to the European ‘single-market’. Policy changes in these countries will arrive quickly as the countries’ accessions become more certain. Pharmaceutical multinationals doing business in these markets must monitor these changes closely, while paying close attention to lessons offered through recent accession markets, like Romania and Bulgaria.
